+Follow
Yeocs818
No personal profile
0
Follow
0
Followers
0
Topic
0
Badge
Posts
Hot
Yeocs818
09-17
Good or bad for Nage
Niagen Bioscience Names Martin Hendrix Strategic Adviser for Corporate Strategy, M&A
Go to Tiger App to see more news
{"i18n":{"language":"en_US"},"userPageInfo":{"id":"4136371379244552","uuid":"4136371379244552","gmtCreate":1673268284109,"gmtModify":1673400156257,"name":"Yeocs818","pinyin":"yeocs818","introduction":"","introductionEn":"","signature":"","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":0,"tweetSize":1,"questionSize":0,"limitLevel":999,"accountStatus":1,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"init","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.10.06","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001,"isScarce":0,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0}],"userBadgeCount":1,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":608775404020544,"gmtCreate":1789653585918,"gmtModify":1789654069293,"author":{"id":"4136371379244552","authorId":"4136371379244552","name":"Yeocs818","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4136371379244552","idStr":"4136371379244552"},"themes":[],"title":"","htmlText":"Good or bad for Nage","listText":"Good or bad for Nage","text":"Good or bad for Nage","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/608775404020544","repostId":"2668962129","repostType":2,"repost":{"id":"2668962129","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"pubTimestamp":1789648373,"share":"https://ttm.financial/m/news/2668962129?lang=en_US&edition=fundamental","pubTime":"2026-09-17 20:32","market":"nz","language":"en","title":"Niagen Bioscience Names Martin Hendrix Strategic Adviser for Corporate Strategy, M&A","url":"https://stock-news.laohu8.com/highlight/detail?id=2668962129","media":"Reuters","summary":"Niagen Bioscience names Martin Hendrix strategic adviser for corporate strategy, M&ANiagen Bioscience’s NAD Pharmaceuticals unit engaged Red Sky Partners as strategic adviser to advance NB4168, a smal","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n <a href=\"https://laohu8.com/S/NAGE\">Niagen Bioscience</a> names Martin Hendrix strategic adviser for corporate strategy, M&A\n </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n Niagen Bioscience’s NAD Pharmaceuticals unit engaged Red Sky Partners as strategic adviser to advance NB4168, a small-molecule investigational drug candidate.\n </li>\n<li>\n Red Sky advisers include Pauline Jen Ryan, a longtime biotech operator and former SVP of corporate development and operations at ImmunoGen.\n </li>\n<li>\n Red Sky also includes Christopher Kiritsy, a former Kos Pharmaceuticals executive involved in building the Niaspan franchise; later co-founded Arisaph Pharmaceuticals.\n </li>\n<li>\n Separately, Niagen brought in Martin Hendrix, a former Nestlé Health Science M&A lead, as strategic adviser on corporate strategy, business development, potential M&A.\n </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Niagen Bioscience Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260917959565) on September 17, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Niagen Bioscience Names Martin Hendrix Strategic Adviser for Corporate Strategy, M&A</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNiagen Bioscience Names Martin Hendrix Strategic Adviser for Corporate Strategy, M&A\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-09-17 20:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n <a href=\"https://laohu8.com/S/NAGE\">Niagen Bioscience</a> names Martin Hendrix strategic adviser for corporate strategy, M&A\n </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n Niagen Bioscience’s NAD Pharmaceuticals unit engaged Red Sky Partners as strategic adviser to advance NB4168, a small-molecule investigational drug candidate.\n </li>\n<li>\n Red Sky advisers include Pauline Jen Ryan, a longtime biotech operator and former SVP of corporate development and operations at ImmunoGen.\n </li>\n<li>\n Red Sky also includes Christopher Kiritsy, a former Kos Pharmaceuticals executive involved in building the Niaspan franchise; later co-founded Arisaph Pharmaceuticals.\n </li>\n<li>\n Separately, Niagen brought in Martin Hendrix, a former Nestlé Health Science M&A lead, as strategic adviser on corporate strategy, business development, potential M&A.\n </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Niagen Bioscience Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260917959565) on September 17, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AGNG":"Global X Aging Population ETF","IYH":"iShares U.S. Healthcare ETF","LU1732800096.USD":"摩根大通环球收益基金A (irc)","SG9999015986.USD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (USD) ACC","TRUH":"VanEck Healthcare TruSector ETF","LU0124676726.USD":"AB SICAV I - SUSTAINABLE US THEMATIC PORTFOLIO \"A\" (USD) ACC","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","FTXH":"First Trust Nasdaq Pharmaceuticals ETF","PJP":"INVESCO PHARMACEUTICALS ETF","LU2237443465.HKD":"abrdn SICAV I - GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) INC","JDOC":"JPMORGAN HEALTHCARE LEADERS ETF","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","VHT":"Vanguard Health Care ETF","LU1732799900.SGD":"JPMorgan Investment Funds - Global Income A (irc) SGD-H","LU0158827948.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"A\" (USD) INC","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU0965509283.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (SGDHDG) INC","ABBV":"艾伯维公司","LU1839511570.USD":"WELLS FARGO GLOBAL FACTOR ENHANCED EQUITY \"I\" (USD) ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","GLAM":"Corgi Beauty, Skincare & Aesthetics ETF","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY \"A\" (USD) ACC","LU1670627923.USD":"M&G (LUX) NORTH AMERICAN DIVIDEND \"A\" (USD) ACC","LU0859254822.USD":"T ROWE PRICE GLOBAL VALUE EQUITY \"A\" (USD) ACC","LU1548497426.USD":"安联环球人工智能AT Acc","LU2237443382.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA USD","NAGE":"Niagen Bioscience","LU0256863902.USD":"ALLIANZ US EQUITY \"AT\" (USD) ACC","LU0726765562.USD":"JPM GLOBAL INCOME \"A\" (USD HEDGED) INC","LU0738911758.USD":"Blackrock Global Equity Income A6 USD","IE00B42XCP33.USD":"GUINNESS GLOBAL EQUITY INCOME \"C\" (USD) INC","LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","LU0545039389.USD":"BGF GLOBAL EQUITY INCOME \"A2\" ACC","RXL":"ProShares Ultra Health Care","XLV":"健康照护类股ETF-SPDR","LU0057025933.USD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"AX\" (USD) ACC","LU1244550494.USD":"FRANKLIN GLOBAL MULTI-ASSET INCOME \"A\" (USDHEDGED) ACC","LU2347655073.USD":"JPM GLOBAL INCOME \"A\" (USDHDG) INC A","SG9999015978.USD":"利安颠覆性创新基金A","LU0868494708.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) INC","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","IXJ":"全球医疗业ETF-iShares","LU2089284900.SGD":"Allianz Global Sustainability Cl AM Dis H2-SGD","FHLC":"Fidelity MSCI Health Care Index","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","LU2129689431.USD":"FRANKLIN GLOBAL INCOME \"A\" (USD) ACC","MEDX":"HORIZON KINETICS MEDICAL ETF","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","PPH":"VanEck Pharmaceutical ETF","LU1670628061.USD":"M&G (LUX) NORTH AMERICAN DIVIDEND \"A\" (USD) INC"},"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260917:nNDL7b0CW9:1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2668962129","content_text":"<a href=\"https://laohu8.com/S/NAGE\">Niagen Bioscience</a> names Martin Hendrix strategic adviser for corporate strategy, M&A\n \n\n\n Niagen Bioscience’s NAD Pharmaceuticals unit engaged Red Sky Partners as strategic adviser to advance NB4168, a small-molecule investigational drug candidate.\n \n\n Red Sky advisers include Pauline Jen Ryan, a longtime biotech operator and former SVP of corporate development and operations at ImmunoGen.\n \n\n Red Sky also includes Christopher Kiritsy, a former Kos Pharmaceuticals executive involved in building the Niaspan franchise; later co-founded Arisaph Pharmaceuticals.\n \n\n Separately, Niagen brought in Martin Hendrix, a former Nestlé Health Science M&A lead, as strategic adviser on corporate strategy, business development, potential M&A.\n \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Niagen Bioscience Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260917959565) on September 17, 2026, and is solely responsible for the information contained therein.","news_type":1,"symbols_score_info":{"IYH":0.6,"JDOC":0.6,"FHLC":0.6,"ABBV":0.9,"RXL":0.6,"TRUH":0.6,"PPH":0.6,"XLV":0.6,"MEDX":0.6,"GLAM":0.6,"IXJ":0.6,"PJP":0.6,"VHT":0.6,"NAGE":0.9,"FTXH":0.6,"AGNG":0.6}},"isVote":1,"tweetType":1,"viewCount":146,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":608775404020544,"gmtCreate":1789653585918,"gmtModify":1789654069293,"author":{"id":"4136371379244552","authorId":"4136371379244552","name":"Yeocs818","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4136371379244552","idStr":"4136371379244552"},"themes":[],"title":"","htmlText":"Good or bad for Nage","listText":"Good or bad for Nage","text":"Good or bad for Nage","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/608775404020544","repostId":"2668962129","repostType":2,"repost":{"id":"2668962129","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"pubTimestamp":1789648373,"share":"https://ttm.financial/m/news/2668962129?lang=en_US&edition=fundamental","pubTime":"2026-09-17 20:32","market":"nz","language":"en","title":"Niagen Bioscience Names Martin Hendrix Strategic Adviser for Corporate Strategy, M&A","url":"https://stock-news.laohu8.com/highlight/detail?id=2668962129","media":"Reuters","summary":"Niagen Bioscience names Martin Hendrix strategic adviser for corporate strategy, M&ANiagen Bioscience’s NAD Pharmaceuticals unit engaged Red Sky Partners as strategic adviser to advance NB4168, a smal","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n <a href=\"https://laohu8.com/S/NAGE\">Niagen Bioscience</a> names Martin Hendrix strategic adviser for corporate strategy, M&A\n </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n Niagen Bioscience’s NAD Pharmaceuticals unit engaged Red Sky Partners as strategic adviser to advance NB4168, a small-molecule investigational drug candidate.\n </li>\n<li>\n Red Sky advisers include Pauline Jen Ryan, a longtime biotech operator and former SVP of corporate development and operations at ImmunoGen.\n </li>\n<li>\n Red Sky also includes Christopher Kiritsy, a former Kos Pharmaceuticals executive involved in building the Niaspan franchise; later co-founded Arisaph Pharmaceuticals.\n </li>\n<li>\n Separately, Niagen brought in Martin Hendrix, a former Nestlé Health Science M&A lead, as strategic adviser on corporate strategy, business development, potential M&A.\n </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Niagen Bioscience Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260917959565) on September 17, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Niagen Bioscience Names Martin Hendrix Strategic Adviser for Corporate Strategy, M&A</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNiagen Bioscience Names Martin Hendrix Strategic Adviser for Corporate Strategy, M&A\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-09-17 20:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n <a href=\"https://laohu8.com/S/NAGE\">Niagen Bioscience</a> names Martin Hendrix strategic adviser for corporate strategy, M&A\n </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n Niagen Bioscience’s NAD Pharmaceuticals unit engaged Red Sky Partners as strategic adviser to advance NB4168, a small-molecule investigational drug candidate.\n </li>\n<li>\n Red Sky advisers include Pauline Jen Ryan, a longtime biotech operator and former SVP of corporate development and operations at ImmunoGen.\n </li>\n<li>\n Red Sky also includes Christopher Kiritsy, a former Kos Pharmaceuticals executive involved in building the Niaspan franchise; later co-founded Arisaph Pharmaceuticals.\n </li>\n<li>\n Separately, Niagen brought in Martin Hendrix, a former Nestlé Health Science M&A lead, as strategic adviser on corporate strategy, business development, potential M&A.\n </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Niagen Bioscience Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260917959565) on September 17, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AGNG":"Global X Aging Population ETF","IYH":"iShares U.S. Healthcare ETF","LU1732800096.USD":"摩根大通环球收益基金A (irc)","SG9999015986.USD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (USD) ACC","TRUH":"VanEck Healthcare TruSector ETF","LU0124676726.USD":"AB SICAV I - SUSTAINABLE US THEMATIC PORTFOLIO \"A\" (USD) ACC","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","FTXH":"First Trust Nasdaq Pharmaceuticals ETF","PJP":"INVESCO PHARMACEUTICALS ETF","LU2237443465.HKD":"abrdn SICAV I - GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) INC","JDOC":"JPMORGAN HEALTHCARE LEADERS ETF","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","VHT":"Vanguard Health Care ETF","LU1732799900.SGD":"JPMorgan Investment Funds - Global Income A (irc) SGD-H","LU0158827948.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"A\" (USD) INC","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU0965509283.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (SGDHDG) INC","ABBV":"艾伯维公司","LU1839511570.USD":"WELLS FARGO GLOBAL FACTOR ENHANCED EQUITY \"I\" (USD) ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","GLAM":"Corgi Beauty, Skincare & Aesthetics ETF","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY \"A\" (USD) ACC","LU1670627923.USD":"M&G (LUX) NORTH AMERICAN DIVIDEND \"A\" (USD) ACC","LU0859254822.USD":"T ROWE PRICE GLOBAL VALUE EQUITY \"A\" (USD) ACC","LU1548497426.USD":"安联环球人工智能AT Acc","LU2237443382.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA USD","NAGE":"Niagen Bioscience","LU0256863902.USD":"ALLIANZ US EQUITY \"AT\" (USD) ACC","LU0726765562.USD":"JPM GLOBAL INCOME \"A\" (USD HEDGED) INC","LU0738911758.USD":"Blackrock Global Equity Income A6 USD","IE00B42XCP33.USD":"GUINNESS GLOBAL EQUITY INCOME \"C\" (USD) INC","LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","LU0545039389.USD":"BGF GLOBAL EQUITY INCOME \"A2\" ACC","RXL":"ProShares Ultra Health Care","XLV":"健康照护类股ETF-SPDR","LU0057025933.USD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"AX\" (USD) ACC","LU1244550494.USD":"FRANKLIN GLOBAL MULTI-ASSET INCOME \"A\" (USDHEDGED) ACC","LU2347655073.USD":"JPM GLOBAL INCOME \"A\" (USDHDG) INC A","SG9999015978.USD":"利安颠覆性创新基金A","LU0868494708.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) INC","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","IXJ":"全球医疗业ETF-iShares","LU2089284900.SGD":"Allianz Global Sustainability Cl AM Dis H2-SGD","FHLC":"Fidelity MSCI Health Care Index","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","LU2129689431.USD":"FRANKLIN GLOBAL INCOME \"A\" (USD) ACC","MEDX":"HORIZON KINETICS MEDICAL ETF","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","PPH":"VanEck Pharmaceutical ETF","LU1670628061.USD":"M&G (LUX) NORTH AMERICAN DIVIDEND \"A\" (USD) INC"},"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260917:nNDL7b0CW9:1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2668962129","content_text":"<a href=\"https://laohu8.com/S/NAGE\">Niagen Bioscience</a> names Martin Hendrix strategic adviser for corporate strategy, M&A\n \n\n\n Niagen Bioscience’s NAD Pharmaceuticals unit engaged Red Sky Partners as strategic adviser to advance NB4168, a small-molecule investigational drug candidate.\n \n\n Red Sky advisers include Pauline Jen Ryan, a longtime biotech operator and former SVP of corporate development and operations at ImmunoGen.\n \n\n Red Sky also includes Christopher Kiritsy, a former Kos Pharmaceuticals executive involved in building the Niaspan franchise; later co-founded Arisaph Pharmaceuticals.\n \n\n Separately, Niagen brought in Martin Hendrix, a former Nestlé Health Science M&A lead, as strategic adviser on corporate strategy, business development, potential M&A.\n \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Niagen Bioscience Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260917959565) on September 17, 2026, and is solely responsible for the information contained therein.","news_type":1,"symbols_score_info":{"IYH":0.6,"JDOC":0.6,"FHLC":0.6,"ABBV":0.9,"RXL":0.6,"TRUH":0.6,"PPH":0.6,"XLV":0.6,"MEDX":0.6,"GLAM":0.6,"IXJ":0.6,"PJP":0.6,"VHT":0.6,"NAGE":0.9,"FTXH":0.6,"AGNG":0.6}},"isVote":1,"tweetType":1,"viewCount":146,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}
